リコンビナント

Anti-Cytokeratin 5 + 6 + 18 抗体 [LP34] (ab40)

Submit a review Submit a question References (11)
Western blot - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)
  • Western blot - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)
  • Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Mouse monoclonal [LP34] to Cytokeratin 5 + 6 + 18
  • Suitable for: WB, IHC-P
  • Reacts with: Human

製品の概要

  • 製品名

    Anti-Cytokeratin 5 + 6 + 18 antibody [LP34]
    Cytokeratin 5 + 6 + 18 一次抗体 製品一覧

  • 製品の詳細

    Mouse monoclonal [LP34] to Cytokeratin 5 + 6 + 18

  • 由来種

    Mouse

  • アプリケーション

    適用あり: WB, IHC-Pmore details
    適用なし: ICC/IF

  • 種交差性

    交差種: Human

  • 免疫原

    Tissue, cells or virus within Human Cytokeratin 5 + 6 + 18. The exact immunogen sequence used to generate this antibody is proprietary information. If additional detail on the immunogen is needed to determine the suitability of the antibody for your needs, please contact our Scientific Support team to discuss your requirements. P13647, P05783, P02538.

    Run BLAST with BLAST the sequence with ExPASy Run BLAST with BLAST the sequence with NCBI

  • ポジティブ･コントロール

    • IHC-P: Human skin and tonsil tissue. Human pancreatic carcinoma and bladder carcinoma tissue. WB: Human skin lysate. HeLa, MCF7 and HepG2 whole cell lysate.

  • 特記事項

    This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com.

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

製品の特性

アプリケーション

The Abpromise guarantee

Abpromise保証は、 次のテスト済みアプリケーションにおけるab40の使用に適用されます

アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。

アプリケーション Abreviews 特記事項
WB
Use a concentration of 0.424 µg/ml.
IHC-P
Use a concentration of 0.085 µg/ml. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
特記事項
WB
Use a concentration of 0.424 µg/ml.
IHC-P
Use a concentration of 0.085 µg/ml. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
  • 追加情報
    Is unsuitable for ICC/IF.

    • ターゲット情報

    • 関連性

      Keratins 5, 6 are members of type II keratins family that are specifically expressed in the inner root sheath of hair follicles. The type II cytokeratins consist of basic or neutral proteins which are arranged in pairs of heterotypic keratin chains coexpressed during differentiation of simple and stratified epithelial tissues. Keratin 18 is memeber of the type I intermediate filament chain keratin 18. Keratin 18, together with its filament partner keratin 8, are perhaps the most commonly found members of the intermediate filament gene family.

    • 細胞内局在

      Cytoplasmic

    • 参照データベース

      • 別名

        • CK5 antibody
        • CYK18 antibody
        • K18 antibody
        • K5 antibody
        • K6IRS2 antibody
        • Keratin 18 antibody
        • Keratin 5 antibody
        • Keratin 72 antibody
        • KRT18 antibody
        • KRT5 antibody
        • KRT6 antibody
        • KRT72 antibody
        see all

      画像

      • Western blot - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)
        Western blot - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)
        All lanes : Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40) at 0.424 µg/ml

        Lane 1 : HeLa (human cervix adenocarcinoma epithelial cell ), whole cell lysate
        Lane 2 : MCF7 (human breast adenocarcinoma epithelial cell), whole cell lysate
        Lane 3 : HepG2 (human hepatocellular carcinoma epithelial cell), whole cell lysate

        Lysates/proteins at 20 µg per lane.

        Secondary
        All lanes : Peroxidase-Conjugated Goat anti-Mouse IgG (H+L) at 1/10000 dilution

        Observed band size: 45 kDa why is the actual band size different from the predicted?



        Blocking/Dilution buffer: 5% NFDM/TBST.

        Exposure times: Lane 1: 15 secs; Lane 2-3: 3 secs.

      • Western blot - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)
        Western blot - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)
        Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40) at 1/1000 dilution + Human skin lysate at 20 µg

        Secondary
        Anti-mouse IgG for IP (HRP) (ab131368) at 1/1000 dilution

        Observed band size: 58 kDa why is the actual band size different from the predicted?


        Exposure time: 114 seconds


        Blocking/Dilution buffer: 5% NFDM/TBST.

      • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)
        Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)

        Immunohistochemical analysis of paraffin-embedded human skin labeling Cytokeratin 5 + 6 + 18 with ab40 at 1/1000 dilution, followed by a ready to use secondary. Positive staining on human skin is observed. The section was incubated with ab40 for 30 mins at RT. The immunostaining staining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with hematoxylin.
        Secondary antibody only control: Used PBS instead of primary antibody, followed by a ready to use secondary. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins.

      • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)
        Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)

        Immunohistochemical analysis of paraffin-embedded human tonsil tissue labeling Cytokeratin 5 + 6 + 18 with ab40 at 0.085µg/ml, followed by a ready to use secondary. Positive staining on the epithelial cells of human tonsil tissue is observed. The section was incubated with ab40 for 30 mins at RT. The immunostaining staining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with hematoxylin.
        Secondary antibody only control: Used PBS instead of primary antibody, followed by a ready to use secondary. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins.

      • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)
        Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)

        Immunohistochemical analysis of paraffin-embedded human bladder carcinoma tissue labeling Cytokeratin 5 + 6 + 18 with ab40 at 0.085µg/ml, followed by a ready to use secondary. Positive staining on human bladder carcinoma tissue is observed. The section was incubated with ab40 for 30 mins at RT. The immunostaining staining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with hematoxylin.
        Secondary antibody only control: Used PBS instead of primary antibody, followed by a ready to use secondary. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins.

      • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)
        Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)

        Immunohistochemical analysis of paraffin-embedded human pancreatic carcinoma tissue labeling Cytokeratin 5 + 6 + 18 with ab40 at 0.085µg/ml, followed by a ready to use secondary. Positive staining on human pancreatic carcinoma tissue is observed. The section was incubated with ab40 for 30 mins at RT. The immunostaining staining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with hematoxylin.
        Secondary antibody only control: Used PBS instead of primary antibody, followed by a ready to use secondary. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins.

      • Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)
        Anti-Cytokeratin 5 + 6 + 18 antibody [LP34] (ab40)

      プロトコール

      To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.

      Click here to view the general protocols

      参考文献 (11)

      ab40 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

      ab40 は 11 報の論文で使用されています。

      • Bergkvist L  et al. Mapping pathogenic processes contributing to neurodegeneration in Drosophila models of Alzheimer's disease. FEBS Open Bio 10:338-350 (2020). PubMed: 31823504
      • Eede P  et al. Interleukin-12/23 deficiency differentially affects pathology in male and female Alzheimer's disease-like mice. EMBO Rep 21:e48530 (2020). PubMed: 32003148
      • Lue LF  et al. Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology. Neurol Ther 8:95-111 (2019). PubMed: 31833027
      • Tejera D  et al. Systemic inflammation impairs microglial Aß clearance through NLRP3 inflammasome. EMBO J 38:e101064 (2019). PubMed: 31359456
      • Fang H  et al. miR-937 regulates the proliferation and apoptosis via targeting APAF1 in breast cancer. Onco Targets Ther 12:5687-5699 (2019). PubMed: 31410016
      View all Publications for this product

      レビューと Q&A

      Show All レビュー Q&A
      レビューを送る 質問を送る

      There are currently no Customer reviews or Questions for ab40.
      Please use the links above to contact us or submit feedback about this product.

      Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
      For licensing inquiries, please contact partnerships@abcam.com